| Literature DB >> 34377475 |
Robert Kaba Alhassan1, Courage Edem Ketor2, Anthony Ashinyo3, Mary Eyram Ashinyo4, Jerry John Nutor5, Conrad Adjadeh6, Emmanuel Sarkodie7.
Abstract
OBJECTIVE: Number of People Living with Human Immune-deficiency Virus in Ghana is over 300,000 and unmet need for antiretroviral therapy is approximately 60%. This study sought to determine the quality of antiretroviral therapy services in selected ART sites in Ghana using the input-process-outcome approach.Entities:
Keywords: Ghana; Quality healthcare; antiretroviral therapy; human immune-deficiency virus; indicators; input-process-outcome
Year: 2021 PMID: 34377475 PMCID: PMC8326618 DOI: 10.1177/20503121211036142
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Summary of demographic characteristics of the population studied (n = 384).
| Variables | Statistic | |
|---|---|---|
| Sex | Frequency (f) |
|
| Male | 70 | 18 |
| Female | 314 | 82 |
| Age | ||
| <15 years | 5 | 1 |
| 15–30 years | 30 | 8 |
| 31–45 years | 157 | 41 |
| 45+ years | 192 | 50 |
| Marital status | ||
| Married | 163 | 43 |
| Co-habiting | 20 | 5 |
| Divorced | 96 | 25 |
| Widowed | 65 | 17 |
| Never-married | 40 | 10 |
| Educational status | ||
| Tertiary | 30 | 8 |
| Secondary | 72 | 19 |
| JHS/Middle level | 178 | 46 |
| Primary | 69 | 18 |
| No-education | 35 | 9 |
| Employment status | ||
| Formal | 43 | 11 |
| Informal | 313 | 82 |
| None | 28 | 7 |
| Residential location | ||
| Urban | 84 | 22 |
| Peri-urban | 43 | 11 |
| Rural | 257 | 67 |
| Religion | ||
| Christian | 356 | 93 |
| Moslem | 28 | 7 |
| Actively enrolled on antiretroviral | ||
| No | 4 | 1 |
| Yes | 380 | 99 |
| Health insurance status | ||
| Uninsured | 4 | 1 |
| Insured | 157 | 41 |
| No record | 223 | 58 |
Source: Field Data (March-May, 2019); *Note: all frequencies and percentages have been rounded off to the nearest decimal; JHS (Junior Higher School); Formal employment (in this context means employment with a government agency).
Demographic Characteristic of Care Providers (n = 16).
| Variable | Freq. (f)* | Percentage (%)* |
|---|---|---|
| Health facility Name | ||
| Hohoe Municipal Hospital | 5 | 31 |
| Jasikan District Hospital | 6 | 38 |
| Volta Regional Hospital | 5 | 31 |
| Professional category | ||
| Nurse | 4 | 25 |
| Pharmacist | 2 | 13 |
| BMS | 2 | 13 |
| Data manager | 2 | 13 |
| Physician | 1 | 6 |
| Pharmacy technician | 1 | 6 |
| Physician assistant | 1 | 6 |
| Disease control | 1 | 6 |
| Nutritionists/dietician | 1 | 6 |
| Orderly | 1 | 6 |
| Location | ||
| Urban | 10 | 63 |
| Peri-Urban | 6 | 34 |
| Total | 16 | 100 |
| Sex | ||
| Male | 9 | 56 |
| Female | 7 | 44 |
| Age | ||
| 18–30 | 7 | 44 |
| >30 | 9 | 56 |
| Marital status | ||
| Married | 11 | 69 |
| Never married/single | 5 | 31 |
| Education | ||
| Tertiary | 15 | 94 |
| Secondary | 1 | 6 |
Source: Field Data (March-May, 2019); *Note: all frequencies and percentages have been rounded off to the nearest decimal.
Summary of resources available for HIV care provision at the three facilities.
| Variables | Sub-categories | Statistic | |
|---|---|---|---|
| Frequency (f) | Percentage (%) | ||
| ARVs | Tenofovir + Lamivudine + Efavirenz | 5 | 83 |
| Tenofovir Lamivudine | 6 | 100 | |
| Efavirenz 600 mg: | 2 | 33 | |
| Nevirapine 200 mg | 6 | 100 | |
| Zidovudine + Lamivudine + Nevirapine | 4 | 67 | |
| Zidovudine + Lamivudine (adult) | 6 | 100 | |
| Zidovudine + Lamivudine (Paed) | 6 | 100 | |
| Zidovudine Syrup | 6 | 100 | |
| Nevirapine Syrup | 4 | 67 | |
| Abacavir + Lamivudine (Paed) | 2 | 33 | |
| Lopinavir/ritonavir (Third line and PEP) | 2 | 33 | |
| Cotrimoxazole Tablet | 5 | 83 | |
| Was Cotrimoxazole supplied from the RMS/NAC | 6 | 100 | |
| Tab Fluconazole 150 mg | 4 | 67 | |
| Tab Fluconazole 200 mg | 0 | 0 | |
| Fluconazole supplied from the RMS/NACP | 0 | 0 | |
| Patients paid for the medication | 2 | 33 | |
| Clinic aids | Nutritious Mixtures (FBF) | 4 | 67 |
| Demonstration Charts for patients | 2 | 33 | |
| Treatment guidelines and/or algorithms | 6 | 100 | |
| Trained staff | Laboratory staff | 6 | 100 |
| Pharmacy staff | 6 | 100 | |
| Prescriber/Clinician | 6 | 100 | |
| Task shift officer | 4 | ||
| Nurse | 6 | 100 | |
| Data manager | 6 | 100 | |
| Counsellor | 6 | 100 | |
| Nutritionist/dietician | 4 | 67 | |
| Social worker | 2 | 33 | |
| Psychosocial support provider | 2 | 33 | |
NACP: National AIDS Control Programme.
Source: Field Data (March-May, 2019); *Note: all frequencies and percentages have been rounded off to the nearest decimal.
Summary of performance on process indicators of quality at the three hospitals.
| Quality indicators | Frequency (f) | Percentage % (95% CI) |
|---|---|---|
| Care during enrolment to HIV clinic | ||
| Received first-time CD4 count within 2 weeks after first HIV clinic visit | 93 | 24.2 (20.2, 28.8) |
| Had baseline liver/renal function tests and haemoglobin (Hb) tests done before initiation of ARVs. | 127 | 33.1 (28.5, 38.0) |
| Opportunistic infection prevention and ART follow-up | ||
| CD4 count < 350 cells/µl and currently on Cotrimoxazole prophylactic therapy | 57 | 14.8 (11.6, 18.8) |
| Patients with continued care | 346 | 90.1 (86.7, 92.7) |
| Patients who had CD4 count measured at least once during the last 6 months | 27 | 7.0 (4.9, 10.1) |
| Patients eligible for ARV who are currently on ARV | 376 | 97.9 (95.9, 99.0) |
| Patients started on ART within 2 weeks after clinical eligibility is confirmed | 271 | 70.6 (65.8, 74.9) |
| Patients started on ART who have viral suppression by 90% | 98 | 25.5 (21.4, 30.1) |
| Patients on NVP who had LFT at least once within 1 month after initiation of NVP-based ART | 40 | 22.0 (16.5, 28.6) |
| Patients on TFV based ARV | 194 | 50.5 (45.5, 55.5) |
| Patients on TFV who had RFT at least once within 1 month after initiation of TFV-based ART | 55 | 28.4(22.4, 35.1) |
| Patients started on ZDV who had HB at least once within 1 month after initiation of ZDV based HAART | 43 | 24.4 (18.6, 31.4) |
| Patients on ART for whom adherence is measured on last three visits | 344 | 89.6 (86.1, 92.3) |
| Patients lost to follow up within the last 6 months | 44 | 11.5 (8.6, 15.1) |
| Record completeness | ||
| Patients with previous ARV regimen changed for whom reason for change in regime is documented | 78 | 20.3 (16.6, 24.7) |
| Patients on ARV who had registered own and contact address of treatment supporter | 335 | 87.2 (83.5, 90.2) |
| Adherence to medications | ||
| Patients on ARV with at least 95% reported adherence on last visit | 337 | 87.8 (84.1, 90.7) |
| Patients on Cotrimoxazole prophylaxis with at least 95% reported adherence on last visit | 282 | 73.4 (68.8, 77.6) |
| Immunologic and clinical response to HIV care | ||
| Patients with CD4 count greater than 200 cells/µL documented (376 not documented, 3 < 200 cells/µL) | 5 | 1.3 (0.5, 3.1) |
| Bedridden or ambulatory patients who have improvement in functional status | 361 | 94.0 (91.1, 96.0) |
ARV: Antiretroviral; HIV: Human immunodeficiency virus; HAART: Highly active antiretroviral therapy; NV: Nevirapine; LFT: Liver functioning test; TFV; ZDV (Zidovudine); HB; CD4 (Cell Surface marker for T-helper lymphocytes).
Source: Field Data (March-May, 2019); *Note: all frequencies and percentages have been rounded off to the nearest decimal.
Summary of mean patient satisfaction scores (n = 384).
| Patient Satisfaction indicators | Statistic | |
|---|---|---|
| Score | SD | |
| Satisfaction with general services | 2.90 | 0.47 |
| Technical Quality | 3.00 | 0.29 |
| Interpersonal relations | 3.25 | 0.41 |
| Communication | 3.08 | 0.41 |
| Financial accessibility | 3.07 | 0.58 |
| Time spent with Clinical Team | 2.98 | 0.54 |
| Accessibility and Convenience | 3.08 | 0.30 |
| Other satisfaction factors | 2.21 | 0.22 |
SD: standard deviation.
Source: Field Data (March-May, 2019); SD (Standard deviation).
Note: mean and standard deviation scores rounded to the nearest. High standard deviation suggests better satisfaction with the service component and vice versa.
Summary of responses from care provider semi-structured interviews.
| Indicators | Statistic | ||
|---|---|---|---|
| During medication/logistic/equipment shortage | Obs. | Freq. (f) | Percent. (%) |
| Tell clients there is shortage | 16 | 2 | 13 |
| Arrange request through stores to Regional Medical Stores (RMS) | 16 | 10 | 63 |
| Contact colleagues from sister facilities for support | 16 | 11 | 69 |
| Average duration for stock replacement | |||
| Not predictable | 16 | 5 | 31 |
| Wait on last mile distribution schedule from RMS | 16 | 6 | 38 |
| Within one week | 16 | 3 | 19 |
| After a month | 16 | 1 | 6 |
| More than a month | 16 | 1 | 6 |
| Medicines/logistical challenges | |||
| Frequent shortages | 15 | 1 | 7 |
| Products with short shelve lives being issued from RMS | 15 | 3 | 20 |
| Lack of Viral Load Machines | 15 | 9 | 60 |
| Lack of reagents | 15 | 1 | 7 |
| Lack of paediatric doses of medications | 15 | 2 | 13 |
| Views on the 90-90-90 strategic goal | |||
| Very ambitious | 16 | 6 | 38 |
| Focus on preventive measures instead of managing PLHIV | 16 | 3 | 19 |
| Just appropriate | 16 | 8 | 50 |
| Not well resourced to help attain goal | 16 | 1 | 6 |
| Ghana’s ability to achieve 90-90-90 strategic goal | |||
| Can be achieved by 2020 | 16 | 1 | 6 |
| Can be achieved but not in 2020 | 16 | 14 | 88 |
| Can only be achieved when there is total committed political will | 16 | 4 | 25 |
| Recommendations towards eradicating HIV by 2030 | |||
| Preventive measures | 16 | 7 | 44 |
| Political will | 16 | 3 | 19 |
| Education and sensitization | 16 | 14 | 88 |
| Efforts targeting males and key populations | 16 | 4 | 25 |
PLHIV: People living with HIV; RMS: Regional Medical Stores.
Source: Field Data (March-May, 2019).
Note: mean and standard deviation scores rounded to the nearest.
Figure 1.Providers’ awareness of Ghana 90-90-90 target and thoughts on ways to improve HIV care quality.
Source: Field Data (March-May, 2019); *Note: mean and standard deviation scores rounded to the nearest.